D. Boral Capital analyst Jason Kolbert downgraded GeoVax Labs (GOVX) to Hold from Buy without a price target The firm says the company is facing a “more constrained” near-term outlook with limited catalysts and tightening capital resources. While the company continues to advance GEO-MVA as a potential diversification solution within the mpox vaccine landscape, its near-term execution risk is elevated, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOVX: